The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-14. Anything still debated is marked as such rather than presented as settled.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection |
| Solubility | Soluble in aqueous buffer | Lipophilic chain lowers pure-water solubility |
| Long-term storage | -20 degrees Celsius or lower | With desiccant, protected from light |
| Short-term storage | 2 to 8 degrees Celsius | For dissolved aliquots |
| Typical purity method | Reversed-phase HPLC | Ultraviolet detection, often with mass confirmation |
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
== Production == Aerated chocolate containing large bubbles is produced via two methods. In the first, melted chocolate is put under a vacuum, where it foams up. As the chocolate cools, and the fats within the chocolate set, the foam structure remains. Sometimes gases such as carbon dioxide are introduced into the mixture before it is placed under the vacuum. Although the method easily permits inclusions such as nougat or nuts, the production is labor-intensive and difficult to keep hygienic. As a result, the second method is more frequently used: working gases into liquid, tempered chocolate under high pressure. Carbon dioxide is mainly used, although others include nitrous oxide. Air is avoided, as oxygen causes chocolate to become rancid. Any gases that do not dissolve are dispersed as bubbles through the chocolate using a beater. As the chocolate is released from the high pressure conditions, the bubbles expand, foaming the product; through this, the amount of pressure directly impacts bubble size. The setting chocolate is deposited in a moulded shell, after which the set interior is capped with liquid tempered chocolate. Factors that affect bubble size include qualities of chocolate, such as viscosity and the rate of setting. The ingredients used, such as emulsifiers and milk fats also impact bubble size; other factors include type of gas and how much pressure is applied. Micro-aerated chocolate is created using the method of beating gases in under high pressure.
On 13 September 1880, a 212-man unit of Cape Mounted Riflemen under Lieutenant Colonel Frederick Carrington crossed into Basutoland in the vicinity of Wepener in order to reinforce the isolated magistracy at Mafeteng. Upon hearing of Carrington's advance, the Mafeteng District magistrate Arthur Barkly set off with 20 policemen to scout ahead. Some 2 miles (3.2 km) from the magistracy, he encountered 300 Basuto warriors commanded by Lerotholi on a hill range overlooking the road. The two parleyed, and Barkly informed Lerotholi of the column's imminent approach and advised him to surrender his arms and withdraw. Lerotholi refused and rode back to his men, after seeing the CMR appear on the rear of the police force. The Basuto then charged down from the hill, and a short skirmish ensued whereby the Basuto suffered light casualties. Carrington's troops then garrisoned Mafeteng, where they were besieged by Lerotholi. On 17 September, a CMR unit was attacked by 700 Basuto outside Mafeteng. Following this attack Sprigg ordered the mobilization of the Cape's armed forces. The army mustered by the Cape government for the conflict, consisting entirely of Cape Colonial Forces troops, was commanded by Brigadier General Charles Clarke, who visited the frontlines only twice during the war, relegating his responsibilities to Adjutant General Major W. F. D. Cochrane and Carrington. Carrington was appointed as the Commandant of the Mafeteng Region and entrusted with a force of approximately 2,000 men.
ribose A monosaccharide sugar which, as D-ribose in its pentose ring form, is one of three primary components of the ribonucleotides from which ribonucleic acid (RNA) molecules are built. Ribose differs from its structural analog deoxyribose only at the 2' carbon, where ribose has an attached hydroxyl group that deoxyribose lacks.
An open-label pilot study on mild and moderate cases was performed in 2020, with mildly positive results. A phase III trial was performed in 2022 in China. In July 2022, China's drug regulator granted conditional approval for it to be used to treat COVID-19, following a local phase III trial. Initially, no detailed description of the said trial was published in any journals, but state media quoted some numbers from the developer: "40% clinical improvement in 7 days by FNC group, compared to 11% in control". It is unclear how such "improvement" is defined. Four phase III clinical trials investigated azvudine's efficacy and safety in adults with mild-to-moderate COVID-19. The findings indicate that azvudine may reduce the time to eliminate detectable levels of virus (viral load) and improve symptoms faster than standard treatment. In trials, it was reported to be safe with few side effects. However, some studies produced inconsistent results in terms of symptom improvement and severe illness prevention. Additionally, the studies tended to use a smaller number of participants than other major COVID-19 drug trials.
== Related problems and reformulations == The hypercycle concept has been continuously studied since its origin. Shortly after Eigen and Schuster published their main work regarding hypercycles, John Maynard Smith raised an objection that the catalytic support for the replication given to other molecules is altruistic. Therefore, it cannot be selected and maintained in a system. He also underlined hypercycle vulnerability to parasites, as they are favoured by selection. Later on, Josef Hofbauer and Karl Sigmund indicated that in reality, a hypercycle can maintain only fewer than five members. In agreement with Eigen and Schuster's principal analysis, they argued that systems with five or more species exhibit limited and unstable cyclic behaviour, because some species can die out due to stochastic events and break the positive feedback loop that sustains the hypercycle. The extinction of the hypercycle then follows. It was also emphasized that a hypercycle size of up to four is too small to maintain the amount of information sufficient to cross the information threshold. Several researchers proposed a solution to these problems by introducing space into the initial model either explicitly or in the form of a spatial segregation within compartments. Bresch et al. proposed a package model as a solution for the parasite problem. Later on, Szathmáry and Demeter proposed a stochastic corrector machine model. Both compartmentalized systems proved to be robust against parasites.
Sources: en.wikipedia.org
=== Development === The series originated from discussions between Toho producers and Yeon Sang-ho in 2018, during which Yeon selected The Human Vapor from Toho's "Transforming Human Series" for its blend of speculative science and human drama. Yeon, known for global hits like Train to Busan (2016) and Netflix's Hellbound (2021), emphasized the original film's "skillful sci-fi expressions" and emotional core, stating: "While it is a sci-fi thriller, at its core, it is a story about people. We focused on treating human emotions with care and portraying the characters’ humanity." Script development took three years, with Ryu Yong-jae—Yeon's collaborator on Parasyte: The Grey (2024)—joining as co-writer. Shinzo Katayama, who was acclaimed for his directing live action TV seriesGannibal (2022), was selected as director for his ability to merge genre elements with intimate storytelling. Katayama, upon revisiting the original, noted: "I was intrigued by its blend of human drama and romantic elements, despite featuring an absurd creature like the Human Vapor." The project represents Netflix's first partnership with Toho, aiming to revive the studio's tokusatsu legacy for global audiences using cutting-edge VFX. Wow Point, the production company behind Parasyte: The Grey, co-produces, infusing Korean expertise in genre storytelling.
==== Dilution effect ==== Death-penalty supporters state that the claim that pancuronium dilutes the sodium thiopental dose is erroneous. Supporters argue that pancuronium and thiopental are commonly used together in everyday surgery and that if there were a dilution effect, it would be a known drug interaction. Drug interactions are a complex topic. Simplistically, drug interactions can be classified as synergistic or inhibitory. Drug interactions can happen in two ways: directly at the place where the drug works or indirectly when the drug is processed in the liver or removed by the kidney. Pancuronium and thiopental have different sites of action, one in the brain and one at the neuromuscular junction. Since the half-life of thiopental is 11.5 hours, the metabolism of the drugs is not an issue when dealing with the short time frame in lethal injections. The only other plausible interpretation would be a direct one, or one in which the two compounds interact with each other. Supporters of the death penalty argue that this theory does not hold true. They state that even if the 100 mg of pancuronium directly prevented 500 mg of thiopental from working, sufficient thiopental to induce coma would be present for 50 hours. In addition, if this interaction did occur, then the pancuronium would be incapable of causing paralysis.
==== MVP runner-up and second player with multiple 40–30 seasons (1999) ==== Bagwell's former high school, Xavier, officially retired his uniform number 9 in a commemoration on January 30, 1999. As the "Killer B's" brand gained increased national attention, journalist Dayn Perry jocosely noted that in 1999 the Astros, "in pursuit of arcane history, used eight players whose last names began with 'B'", including Bagwell, Paul Bako, Glen Barker, Bell, Sean Bergman, Lance Berkman, Biggio, and Tim Bogar. On April 21, Bagwell hit three home runs in a 10–3 win against the Chicago Cubs at Wrigley Field, his second career three-home run game. The second home run allowed him to overtake Wynn as the Astros' all-time home run leader at 224 and he tied a career-high with six RBI in one game. Bagwell produced another three-home run game on June 9 against the Chicago White Sox that was a grand slam short of the "home run cycle", accounted with a solo home run, a three-run home run, and a two-run home run, respectively. The two three-home run games made him the only player to accomplish this feat at two different stadiums in Chicago in the same season. Nominated to his fourth career All-Star Game, Bagwell to that point in the season had scored or driven in 28.6% of the Astros' runs, the highest portion of a team's offense for which any one player in MLB accounted. He was first in the NL in walks (83), runs scored (81) and OBP (.464), second in home runs (28), RBI (78) and SLG (.648) and stole 17 bases while Houston remained percentage points behind Cincinnati for first in the division.
Mephedrone is one of hundreds of designer drugs or legal highs that have been reported in recent years, including artificial chemicals such as synthetic cannabis and semisynthetic substances such as methylhexanamine. These drugs are primarily developed to avoid being controlled by laws against illegal drugs, thus giving them the label of designer drugs. According to the European Monitoring Centre for Drugs and Drug Addiction, the synthesis of mephedrone was first reported in 1929 by Saem de Burnaga Sanchez in the Bulletin de la Société Chimique de France, under the name "toluyl-alpha-monomethylaminoethylcetone", but the compound remained an obscure product of academia until 2003, when it was "re-discovered" and publicised by an underground chemist on The Hive website, registered to a Portuguese IP working under the pseudonym "Kinetic". Kinetic posted on the site, "I've been bored over the last couple of days and had a few fun reagents lying around, so I thought I'd try and make some 1-(4-methylphenyl)-2-methylaminopropanone hydrochloride, or 4-methylmethcathinone." before going on to describe that after consuming it, the user had a "fantastic sense of well-being that I haven't got from any drug before except my beloved Ecstasy." After the initial description of mephedrone's qualitative effects by Kinetic, the drug was commercially introduced in Israel by a mathematician named Ezekiel Golan or "Dr. Z". A drug similar to mephedrone, containing cathinone, was sold legally in Israel from around 2004, under the name hagigat.
In the European Union, a biological medicinal product is one of the active substance(s) produced from or extracted from a biological (living) system, and requires, in addition to physicochemical testing, biological testing for full characterisation. The characterisation of a biological medicinal product is a combination of testing the active substance and the final medicinal product together with the production process and its control. For example: Production process – it can be derived from biotechnology or from other technologies. It may be prepared using more conventional techniques as is the case for blood or plasma-derived products and a number of vaccines. Active substance – consisting of entire microorganisms, mammalian cells, nucleic acids, proteinaceous, or polysaccharide components originating from a microbial, animal, human, or plant source. Mode of action – therapeutic and immunological medicinal products, gene transfer materials, or cell therapy materials.
Sources: en.wikipedia.org
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.
Lyophilised powder is generally held at minus twenty degrees Celsius or lower for long-term storage. Once dissolved, aliquots are kept at two to eight degrees Celsius for short periods and should not be repeatedly frozen and thawed.
Photo-oxidation can modify tryptophan, methionine, and tyrosine residues, altering the structure. Amber glass containers or foil wrapping are routine measures to reduce light exposure.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.